A phase I COVID-19 vaccine trial among SARS-CoV-2 seronegative and seropositive individuals in Uganda utilizing a self-amplifying RNA vaccine platform: Screening and enrollment experiences-Reference-Cited by-同舟云学术

A phase I COVID-19 vaccine trial among SARS-CoV-2 seronegative and seropositive individuals in Uganda utilizing a self-amplifying RNA vaccine platform: Screening and enrollment experiences

Published:2023-08 Issue:2 Volume:19 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Kitonsa Jonathan¹^ORCID,Kamacooko Onesmus¹,Ruzagira Eugene¹,Nambaziira Florence¹,Abaasa Andrew¹²,Serwanga Jennifer¹,Gombe Ben¹,Lunkuse Jane¹,Naluyinda Hadijah¹,Tukamwesiga Naboth¹,Namata Tamara¹,Kigozi Antony¹,Kafeero Paddy¹,Basajja Vincent¹,Joseph Sarah³,Pierce Benjamin F.³,Shattock Robin³,Kaleebu Pontiano¹

Affiliation:

1. Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda

2. Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK

3. Department of Infectious Disease, Imperial College London, London, UK

Funder

Department of Health

Engineering and Physical Sciences Research Council

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link